| Nome |
# |
|
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial), file e0d6c927-4ef9-fcf8-e053-d805fe0aa794
|
444
|
|
Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months, file e0d6c927-4a45-fcf8-e053-d805fe0aa794
|
300
|
|
Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience., file e0d6c927-4efc-fcf8-e053-d805fe0aa794
|
273
|
|
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer, file e0d6c928-ecf7-fcf8-e053-d805fe0aa794
|
266
|
|
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, file e0d6c930-e9b0-fcf8-e053-d805fe0aa794
|
259
|
|
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, file e0d6c926-e72d-fcf8-e053-d805fe0aa794
|
213
|
|
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, file e0d6c92c-3dc5-fcf8-e053-d805fe0aa794
|
202
|
|
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer, file e0d6c92c-198b-fcf8-e053-d805fe0aa794
|
195
|
|
New Prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC)., file e0d6c927-4fef-fcf8-e053-d805fe0aa794
|
165
|
|
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis, file e0d6c928-e9a1-fcf8-e053-d805fe0aa794
|
165
|
|
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file e0d6c928-e94d-fcf8-e053-d805fe0aa794
|
162
|
|
KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: a case-control study., file e0d6c927-5065-fcf8-e053-d805fe0aa794
|
159
|
|
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients, file e0d6c931-1d35-fcf8-e053-d805fe0aa794
|
143
|
|
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients, file e0d6c928-e8df-fcf8-e053-d805fe0aa794
|
140
|
|
KRAS and BRAF genotyping of synchronous colorectal carcinomas., file e0d6c927-102d-fcf8-e053-d805fe0aa794
|
131
|
|
Feasibility and efficacy of 223Ra-dichloride (223Ra) to treat bone metastases in patients (pts) with castration resistant prostate cancer (mCRPC), file e0d6c927-46b5-fcf8-e053-d805fe0aa794
|
121
|
|
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA, file e0d6c929-f65c-fcf8-e053-d805fe0aa794
|
119
|
|
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients., file e0d6c927-5350-fcf8-e053-d805fe0aa794
|
117
|
|
Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer, file e0d6c929-bf6d-fcf8-e053-d805fe0aa794
|
115
|
|
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab, file e0d6c92c-5637-fcf8-e053-d805fe0aa794
|
109
|
|
Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials, file e0d6c928-f434-fcf8-e053-d805fe0aa794
|
107
|
|
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group, file e0d6c92c-363a-fcf8-e053-d805fe0aa794
|
105
|
|
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab, file e0d6c92c-1e43-fcf8-e053-d805fe0aa794
|
103
|
|
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data, file e0d6c928-f2b5-fcf8-e053-d805fe0aa794
|
100
|
|
Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer, file e0d6c92b-0288-fcf8-e053-d805fe0aa794
|
97
|
|
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment, file e0d6c92a-0b5b-fcf8-e053-d805fe0aa794
|
93
|
|
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib, file e0d6c927-46be-fcf8-e053-d805fe0aa794
|
91
|
|
null, file e0d6c927-e576-fcf8-e053-d805fe0aa794
|
85
|
|
Inherited mutations in breast cancer susceptibility genes among a triple negative breast cancer color unselected for family history of breast cancer, file e0d6c927-46c3-fcf8-e053-d805fe0aa794
|
83
|
|
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management, file e0d6c928-f3fe-fcf8-e053-d805fe0aa794
|
72
|
|
KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA, file e0d6c927-4b88-fcf8-e053-d805fe0aa794
|
71
|
|
Incremental value of 3D echocardiography and two-dimensional speckle tracking in the early detection of cardiotoxicity linked to chemotherapy and trastuzumab in patients with HER-2 positive breast cancer, file e0d6c927-4e7b-fcf8-e053-d805fe0aa794
|
62
|
|
Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer (CRC), file e0d6c927-4ffc-fcf8-e053-d805fe0aa794
|
58
|
|
Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670), file e0d6c928-e94c-fcf8-e053-d805fe0aa794
|
51
|
|
regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled, phase 3 trial., file e0d6c926-df37-fcf8-e053-d805fe0aa794
|
49
|
|
Management of peritoneal carcinomatosis with cytoreductive surgery combined with intraperitoneal chemohyperthermia at a novel italian center, file e0d6c92f-721a-fcf8-e053-d805fe0aa794
|
47
|
|
T-DM1 for HER2 positive advanced breast cancer:a single institution, "real-life" experience., file e0d6c927-4ea9-fcf8-e053-d805fe0aa794
|
46
|
|
null, file e0d6c927-4b86-fcf8-e053-d805fe0aa794
|
27
|
|
The role of clinicopathologic and molecular prognostic factors in the post-mastectomy radiotherapy (PMRT): a retrospective analysis of 912 patients, file e0d6c929-5295-fcf8-e053-d805fe0aa794
|
27
|
|
Zebrafish patient-derived xenografts identify chemo-response in pancreatic ductal adenocarcinoma patients, file e0d6c931-aabb-fcf8-e053-d805fe0aa794
|
23
|
|
DPYD c.1905+1G>A and c.2846 A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer., file e0d6c92b-676c-fcf8-e053-d805fe0aa794
|
17
|
|
Folfoxiri in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO)., file e0d6c926-deb9-fcf8-e053-d805fe0aa794
|
15
|
|
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer, file e0d6c929-e8c2-fcf8-e053-d805fe0aa794
|
11
|
|
Management of thyrotoxicosis induced by PD1 or PD-L1 blockade, file e0d6c931-4554-fcf8-e053-d805fe0aa794
|
11
|
|
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer, file e0d6c92a-065f-fcf8-e053-d805fe0aa794
|
10
|
|
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial, file e0d6c92f-ec8e-fcf8-e053-d805fe0aa794
|
10
|
|
Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications, file 1ac8957d-17c8-463b-b6a1-89c36c80e532
|
9
|
|
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis, file e0d6c926-df3a-fcf8-e053-d805fe0aa794
|
8
|
|
Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients, file e0d6c92b-384d-fcf8-e053-d805fe0aa794
|
7
|
|
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study, file e0d6c92f-bed6-fcf8-e053-d805fe0aa794
|
7
|
|
Detailing the ultrastructure’s increase of prion protein in pancreatic adenocarcinoma, file e0d6c931-9168-fcf8-e053-d805fe0aa794
|
7
|
|
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan, file e0d6c926-4717-fcf8-e053-d805fe0aa794
|
5
|
|
Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients, file e0d6c927-f523-fcf8-e053-d805fe0aa794
|
5
|
|
Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine, file e0d6c92f-e1e2-fcf8-e053-d805fe0aa794
|
5
|
|
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells, file e0d6c925-eb07-fcf8-e053-d805fe0aa794
|
4
|
|
Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients, file e0d6c928-42e0-fcf8-e053-d805fe0aa794
|
4
|
|
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers, file e0d6c92a-b1ad-fcf8-e053-d805fe0aa794
|
4
|
|
null, file e0d6c930-98ae-fcf8-e053-d805fe0aa794
|
4
|
|
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients., file e0d6c926-3fb5-fcf8-e053-d805fe0aa794
|
3
|
|
Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer., file e0d6c92a-000b-fcf8-e053-d805fe0aa794
|
3
|
|
Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation, file e0d6c92b-4527-fcf8-e053-d805fe0aa794
|
3
|
|
The winding roadmap of biomarkers toward clinic: Lessons from predictors of resistance to anti-EGFRs in metastatic colorectal cancer, file e0d6c92c-0285-fcf8-e053-d805fe0aa794
|
3
|
|
Current status and perspectives in immunotherapy for metastatic melanoma, file e0d6c92c-17ad-fcf8-e053-d805fe0aa794
|
3
|
|
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer, file e0d6c92c-d5ee-fcf8-e053-d805fe0aa794
|
3
|
|
Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses, file e0d6c92e-65f3-fcf8-e053-d805fe0aa794
|
3
|
|
Maintenance Therapy with Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients with RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial, file e0d6c92e-6b96-fcf8-e053-d805fe0aa794
|
3
|
|
Clinical and economic effect of administration of red blood product transfusions in an outpatient supportive care cancer service, file e0d6c92e-b61a-fcf8-e053-d805fe0aa794
|
3
|
|
FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer, file e0d6c92e-b622-fcf8-e053-d805fe0aa794
|
3
|
|
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer, file e0d6c92f-d335-fcf8-e053-d805fe0aa794
|
3
|
|
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies, file e0d6c930-f2c0-fcf8-e053-d805fe0aa794
|
3
|
|
Role of Baseline Computed-Tomography-Evaluated Body Composition in Predicting Outcome and Toxicity from First-Line Therapy in Advanced Gastric Cancer Patients, file e0d6c931-1b16-fcf8-e053-d805fe0aa794
|
3
|
|
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, file 1761d038-570a-494e-8068-60f2f66b9017
|
2
|
|
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction, file e0d6c926-2991-fcf8-e053-d805fe0aa794
|
2
|
|
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?, file e0d6c926-3edb-fcf8-e053-d805fe0aa794
|
2
|
|
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab., file e0d6c926-4256-fcf8-e053-d805fe0aa794
|
2
|
|
Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680â7, file e0d6c929-c55e-fcf8-e053-d805fe0aa794
|
2
|
|
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients, file e0d6c929-fb96-fcf8-e053-d805fe0aa794
|
2
|
|
Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial, file e0d6c92b-4fcb-fcf8-e053-d805fe0aa794
|
2
|
|
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer, file e0d6c92b-6b0a-fcf8-e053-d805fe0aa794
|
2
|
|
null, file e0d6c92b-f07b-fcf8-e053-d805fe0aa794
|
2
|
|
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study, file e0d6c92c-0d56-fcf8-e053-d805fe0aa794
|
2
|
|
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): A phase III, international, randomized, placebo-controlled study, file e0d6c92c-198e-fcf8-e053-d805fe0aa794
|
2
|
|
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project, file e0d6c92c-23c3-fcf8-e053-d805fe0aa794
|
2
|
|
Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer, file e0d6c92c-2675-fcf8-e053-d805fe0aa794
|
2
|
|
null, file e0d6c92c-2702-fcf8-e053-d805fe0aa794
|
2
|
|
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study), file e0d6c92c-463f-fcf8-e053-d805fe0aa794
|
2
|
|
Interprofessional spiritual care in oncology: a literature review, file e0d6c92c-d5e8-fcf8-e053-d805fe0aa794
|
2
|
|
Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial, file e0d6c92d-077c-fcf8-e053-d805fe0aa794
|
2
|
|
null, file e0d6c92d-a6d5-fcf8-e053-d805fe0aa794
|
2
|
|
Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients, file e0d6c92d-aaf3-fcf8-e053-d805fe0aa794
|
2
|
|
Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer, file e0d6c92e-5a2a-fcf8-e053-d805fe0aa794
|
2
|
|
Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer, file e0d6c92e-a628-fcf8-e053-d805fe0aa794
|
2
|
|
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials, file e0d6c92f-8490-fcf8-e053-d805fe0aa794
|
2
|
|
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer, file e0d6c92f-93e6-fcf8-e053-d805fe0aa794
|
2
|
|
Polymorphisms within immune regulatory pathways predict cetuximab efficacy and survival in metastatic colorectal cancer patients, file e0d6c92f-97b9-fcf8-e053-d805fe0aa794
|
2
|
|
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO, file e0d6c92f-97c3-fcf8-e053-d805fe0aa794
|
2
|
|
Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in folfoxiri plus bevacizumab: Analysis of the tribe trial, file e0d6c92f-9e5c-fcf8-e053-d805fe0aa794
|
2
|
|
Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients, file e0d6c92f-be74-fcf8-e053-d805fe0aa794
|
2
|
|
Immune checkpoint inhibitors in pmmr metastatic colorectal cancer: A tough challenge, file e0d6c92f-d87f-fcf8-e053-d805fe0aa794
|
2
|
|
Quantitative evidence for early metastatic seeding in colorectal cancer, file e0d6c930-9b09-fcf8-e053-d805fe0aa794
|
2
|
| Totale |
5.435 |